Professional Summary

Professional Overview

Ron Gimbel is a seasoned finance executive with extensive experience in the pharmaceutical and life sciences industry. As the Chief Financial Officer at Sumitomo Pharma America, Inc., he leverages his deep expertise in financial management, strategic planning, and operational excellence to drive the company's growth and profitability.

Experience Summary

Current Role

As the Chief Financial Officer at Sumitomo Pharma America, Inc., Ron is responsible for overseeing the company's financial operations, including financial planning and analysis, accounting, treasury, and risk management. He plays a crucial role in aligning the company's financial strategies with its overall business objectives, ensuring efficient resource allocation and informed decision-making.

Career Progression

Prior to his current role, Ron held various leadership positions at Bristol Myers Squibb, including Vice President Finance – Research & Development, Chief Audit Executive, and Vice President and Head of Finance - Global Manufacturing and Supply. He also served as the Chief Financial Officer at Flagship Labs and Enterprise at Flagship Pioneering, where he contributed to the successful development and commercialization of innovative biopharmaceutical products.

Throughout his career, Ron has demonstrated a proven track record of driving financial and operational excellence. He has played a pivotal role in implementing robust financial controls, improving financial reporting, and optimizing resource allocation to support the growth and success of the organizations he has served.

Academic Background

Ron holds a Bachelor's degree in Accounting from the University of Pennsylvania and is a Certified Public Accountant (CPA).

Areas of Expertise

• Financial management and reporting

• Strategic planning and business partnering

• Operational optimization and cost management

• Risk management and internal controls

• Mergers, acquisitions, and integration

• Financial and compliance auditing

Professional Impact

During his tenure at Bristol Myers Squibb, Ron played a key role in the successful integration of Celgene Corporation, a $74 billion acquisition that expanded the company's portfolio and pipeline. He also led the implementation of a global financial shared services model, resulting in enhanced efficiency and cost savings.

As the Chief Financial Officer at Flagship Pioneering, Ron played a pivotal role in the successful financing and commercialization of several innovative biopharmaceutical products, contributing to the company's growth and industry impact.

Conclusion

With a proven track record of financial leadership and a deep understanding of the pharmaceutical and life sciences industry, Ron Gimbel is well-positioned to drive Sumitomo Pharma America, Inc.'s financial strategies and contribute to its long-term success. His expertise, coupled with his collaborative approach and commitment to operational excellence, make him a valuable asset to the organization.